首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1297771

全球膽固醇檢測產品市場 - 2023-2030年

Global Cholesterol Testing Products Market - 2023-2030

出版日期: 2023年06月15日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

全球膽固醇檢測產品的市場規模在2022年達到85億美元，預計到2030年將見證有利可圖的成長，達到159億美元。在2023-2030年的預測期間，該市場的年復合成長率為8.3%。

膽固醇檢測產品是用於測量和監測血液中膽固醇水平的醫療設備、檢測試劑盒、試劑和消耗品。血液中的高膽固醇水平會增加心血管疾病的風險，如心臟病發作和中風。醫療保健提供者使用這些產品來測量和監測心血管疾病患者或有風險的患者的膽固醇水平。

膽固醇檢測產品的市場是由人們對與高膽固醇水平相關的健康風險，如心血管疾病、中風和糖尿病的認知不斷提高所推動的。這導致醫療機構、病人和個人對膽固醇檢測產品的需求增加。由於生活方式疾病、膽固醇監測意識的提高以及膽固醇檢測產品的技術進步，市場預計將成長。

市場動態

生活方式疾病的發病率不斷增加

生活方式疾病的日益盛行是推動膽固醇檢測產品市場成長的主要因素之一。肥胖、糖尿病和高血壓等生活方式疾病是高膽固醇水平和心血管疾病的已知風險因素。

例如，根據世界衛生組織的數據，非傳染性疾病，包括心血管疾病、糖尿病和癌症，約佔全球所有死亡的71%。不健康的生活習慣，如缺乏體力活動、不健康的飲食和吸煙，是這些疾病的關鍵風險因素。

隨著這些生活方式疾病的發病率不斷上升，對有效的預防、診斷和管理策略的需求也越來越大。膽固醇檢測產品在早期檢測和管理高膽固醇水平和心血管疾病方面發揮著關鍵作用。這增加了對膽固醇檢測產品的需求，因為醫療保健提供者尋求解決日益成長的生活方式疾病的負擔，並改善病人的結果。

產品的高成本和嚴格的監管要求

該市場的主要挑戰是膽固醇檢測產品的高成本和嚴格的監管要求。膽固醇檢測產品的開發和商業化涉及大量的研究和開發成本，這可能導致最終產品的高價格。這可能會限制低收入國家和服務不足人群的獲得，並限制新興經濟體的市場成長。

膽固醇檢測產品的監管要求可能很嚴格，特別是在已開發國家。這些要求包括上市前的批准，臨床試驗，以及遵守標準和法規。不遵守法規可能導致罰款和其他處罰，使中小型企業難以進入市場並與大型企業競爭。

COVID-19影響分析

COVID-19大流行病對膽固醇檢測產品市場產生了影響。在大流行的早期階段，醫療系統被COVID-19患者淹沒，導致選擇性手術的減少，包括常規膽固醇檢測。然而，隨著大流行病的持續和醫療系統適應新常態，對膽固醇檢測產品的需求開始恢復。

此外，大流行病導致了遠程醫療和遠程監控的激增，這為膽固醇檢測產品創造了新的機會。患者現在可以遠程獲得膽固醇檢測產品，並接受醫療服務提供者的虛擬諮詢，改善了獲得護理的機會，減少了接觸COVID-19的風險。

俄羅斯-烏克蘭衝突分析

俄羅斯和烏克蘭之間的衝突已經極大地影響了全球政治和經濟格局，包括醫療保健行業。在烏克蘭，競爭導致國內流離失所者的數量大幅增加，醫療設施和基礎設施遭到破壞。

在俄羅斯，衝突導致了貿易限制和經濟制裁，限制了醫療設備和用品的供應，破壞了供應鏈，使公司更難製造和分銷醫療保健產品。這些限制限制了醫療設備和用品的供應，擾亂了供應鏈，使公司更難製造和分銷保健產品。

Market Overview

The Global Cholesterol Testing Products Market size reached US$ 8.5 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 15.9 billion by 2030. The market is exhibiting at a CAGR of 8.3% during the forecast period 2023-2030.

Cholesterol testing products are medical devices, test kits, reagents, and consumables used to measure and monitor cholesterol levels in the blood. High cholesterol levels in the blood can increase the risk of cardiovascular diseases such as heart attack and stroke. Healthcare providers use these products to measure and monitor cholesterol levels in patients with or at risk of cardiovascular diseases.

The market for cholesterol testing products is driven by a growing awareness of the health risks associated with high cholesterol levels, such as cardiovascular disease, stroke, and diabetes. This has led to an increased demand for cholesterol testing products by healthcare providers, patients, and individuals. The market is expected to grow due to lifestyle diseases, increased awareness of cholesterol monitoring, and technological advancements in cholesterol testing products.

Market Dynamics

Increasing Prevalence of Lifestyle Diseases

The increasing prevalence of lifestyle diseases is one of the major factors driving the growth of the cholesterol-testing products market. Lifestyle diseases such as obesity, diabetes, and hypertension are known risk factors for high cholesterol levels and cardiovascular diseases.

For instance, According to the World Health Organization, noncommunicable diseases, including cardiovascular diseases, diabetes, and cancer, account for approximately 71% of all deaths globally. Unhealthy lifestyle habits such as lack of physical activity, unhealthy diets, and tobacco use are key risk factors for these diseases.

As the prevalence of these lifestyle diseases continues to rise, there is a growing need for effective prevention, diagnosis, and management strategies. Cholesterol testing products play a crucial role in detecting and managing high cholesterol levels and cardiovascular diseases early. This has increased the demand for cholesterol testing products as healthcare providers seek to address the growing burden of lifestyle diseases and improve patient outcomes.

High Cost of the Products and Stringent Regulatory Requirements

The market's major challenges are the high cost of cholesterol testing products and stringent regulatory requirements. The development and commercialization of cholesterol testing products involves significant research and development costs, which can lead to a high price of the final products. This can limit accessibility in low-income countries and underserved populations and restrict the market growth in emerging economies.

The regulatory requirements for cholesterol testing products can be stringent, particularly in developed countries. These requirements include pre-market approval, clinical trials, and compliance with standards and regulations. Failure to comply with regulations can result in fines and other penalties, making it difficult for small and medium-sized enterprises to enter the market and compete with larger players.

COVID-19 Impact Analysis

The COVID-19 pandemic has had an impact on the cholesterol testing products market. During the early stages of the pandemic, healthcare systems were overwhelmed with COVID-19 patients, leading to a decrease in elective procedures, including routine cholesterol testing. However, as the pandemic continued and healthcare systems adapted to the new normal, the demand for cholesterol testing products began to recover.

Additionally, the pandemic has led to a surge in telemedicine and remote monitoring, which has created new opportunities for cholesterol testing products. Patients can now access cholesterol testing products remotely and receive virtual consultations with healthcare providers, improving access to care and reducing the risk of exposure to COVID-19.

Russia-Ukraine Conflict Analysis

The conflict between Russia and Ukraine has significantly impacted the global political and economic landscape, including the healthcare industry. In Ukraine, the competition has caused a significant increase in the number of internally displaced persons and destroyed healthcare facilities and infrastructure.

In Russia, the conflict has led to trade restrictions and economic sanctions, which have limited the availability of medical equipment and supplies, and disrupted supply chains, making it more difficult for companies to manufacture and distribute healthcare products. These restrictions have limited the availability of medical equipment and supplies and disrupted supply chains, making it more difficult for companies to manufacture and distribute healthcare products.

Segment Analysis

The Global Cholesterol Testing Products Market is segmented based on product, test type, end-user, and region.

The devices segment is expected to dominate the market share based on product.

The devices segment accounted for the highest market stake, accounting for approximately 52.4% of the cholesterol testing products market in 2022 due to the increasing demand for reliable and accurate devices. These devices include handheld cholesterol testing devices, point-of-care testing devices, and home cholesterol testing kits. Additionally, the growing trend of self-monitoring of cholesterol levels has increased demand for home cholesterol testing kits.

The devices segment is expected to witness significant growth in the coming years due to technological advancements, increasing demand for point-of-care testing, and the rising prevalence of lifestyle diseases such as diabetes and obesity. The development of portable and wireless cholesterol testing devices is also expected to boost the growth of this segment.

Geographical Analysis

North America will capture the highest market share due to the increased prevalence of cardiovascular diseases and demand for POCT Products.

North America has a significant market share of around 39.6% for the cholesterol testing products market due to the increased prevalence of cardiovascular diseases and the growing demand for point-of-care testing (POCT) products. Cardiovascular diseases (CVDs) are a major public health concern in North America, and high cholesterol is a significant risk factor for developing CVDs. The increasing prevalence of CVDs in the region has led to a growing demand for cholesterol testing products, including laboratory-based and POCT devices.

Furthermore, the demand for POCT products is increasing in North America, driven by the need for rapid and accurate testing results, convenience, and cost-effectiveness. POCT devices allow cholesterol testing to be performed at the point of care, such as in a doctor's office or clinic, without requiring samples to be sent to a laboratory for analysis.

In addition, the region is home to several key players in the cholesterol testing products market, who are constantly introducing new and innovative products to meet the growing demand for cholesterol testing. These companies are also investing in research and development to improve the accuracy and reliability of cholesterol testing products.

Competitive Landscape

The major global players in the market include: Abbott Laboratories, F. Hoffmann-La Roche AG, Siemens Healthineers, Danaher Corporation, Bio-Rad Laboratories Inc., ACON Laboratories Inc., Lepu Medical Technology, SD BIOSENSOR INC., Ciga Healthcare, and SpectraCell Laboratories Inc.

Why Purchase the Report?

To visualize the Global Cholesterol Testing Products Market segmentation based on product, test type, end-user, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous cholesterol testing products market-level data points with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The Global Cholesterol Testing Products Market Report Would Provide Approximately 54 Tables, 46 Figures and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product
3.2. Snippet by Test Type
3.3. Snippet by End-User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increased Prevalence of Lifestyle Diseases
- 4.1.2. Restraints
  - 4.1.2.1. High Cost of the Products and Stringent Regulatory Requirements
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Post COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer's Strategic Initiatives
6.6. Conclusion

7. By Product

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 7.1.2. Market Attractiveness Index, By Product
7.2. Devices*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.3. Handheld cholesterol monitoring devices
- 7.2.4. Bench-top cholesterol monitoring devices
- 7.2.5. Consumables
7.3. Test Kits
7.4. Others

8. By Test Type

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 8.1.2. Market Attractiveness Index, By Test Type
8.2. Total Cholesterol*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Low-Density Lipoprotein (LDL) Cholesterol
8.4. High-Density Lipoprotein (HDL) Cholesterol
8.5. Triglycerides
8.6. Very Low-Density Lipoprotein (VLDL) Cholesterol

9. By End-User

9.1. Hospitals
9.2. Diagnostic centers
9.3. Home healthcare
9.4. Research laboratories

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. The U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. The UK
  - 10.3.6.3. France
  - 10.3.6.4. Italy
  - 10.3.6.5. Spain
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan
  - 10.5.6.4. Australia
  - 10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Abbott Laboratories*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. F. Hoffmann-La Roche AG
12.3. Siemens Healthineers
12.4. Danaher Corporation
12.5. Bio-Rad Laboratories Inc.
12.6. ACON Laboratories Inc.
12.7. Lepu Medical Technology
12.8. SD BIOSENSOR INC.
12.9. Ciga Healthcare
12.10. SpectraCell Laboratories Inc.

LIST NOT EXHAUSTIVE